Malignant neoplastic disease

Active Ingredient: Ifosfamide

Indication for Ifosfamide

Population group: only adults (18 years old or older)

Ifosfamide is a cytotoxic drug for the treatment of malignant disease. As a single agent it has successfully produced objective remissions in a wide range of malignant conditions. Ifosfamide is also frequently used in combination with other cytotoxic drugs, radiotherapy and surgery.

For this indication, competent medicine agencies globally authorize below treatments:

5-12 g/m² once a day

Route of admnistration

Intravenous

Defined daily dose

5 - 12 g per m² of body surface area (BSA)

Dosage regimen

From 5 To 12 g per m² of body surface area (BSA) once every day

Detailed description

A guide to the dosage regimens used for most indications is given below:

8-12 g/m² equally fractionated as single daily doses over 3-5 days every 2-4 weeks.
5-6 g/m² (maximum 10 g) given as a 24 hour infusion every 3–4 weeks.

The frequency of dosage is determined by the degree of myelosuppression and the time taken to recover adequate bone marrow function. The usual number of courses given is 4, but up to 7 (6 by 24 hour infusion) courses have been given. Re-treatment has been given following relapse.

During or immediately after administration, adequate amounts of fluid should be ingested or infused to force diuresis in order to reduce the risk of urothelial toxicity.

For prophylaxis of haemorrhagic cystitis, ifosfamide should be used in combination with mesna.

Active ingredient

Ifosfamide
Ifosfamide is an antineoplastic, a cytotoxic alkylating agent. It is a prodrug and shows no in vitro cytotoxic activity until activated by microsomal enzymes. The cytotoxic activity of ifosfamide (alkylation of the nucleophilic centres in the cells) is associated with the activated oxazaphosphorine ring hydroxylated at the C4 atom which interacts with DNA-DNA cross linking. This activity manifests itself by blocking the late S and early G2 phases of the cell cycle. Read more about Ifosfamide

Related medicines

Structured Product Labeling (SPL/PLR) 2018: IFEX Powder for solution for injection

Summary of Product Characteristics (SPC) 2016: IFOSFAMIDE INJECTION Powder for concentrate for solution for infusion

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.